HealthDay News — The sodium glucose co-transporter 2 inhibitor tofogliflozin is effective for reducing fasting plasma glucose and body weight, particularly in patients with a high insulin level at baseline, according to a study published online in the Journal of Diabetes Investigation.
Kazuyuki Tobe, MD, PhD, from the University of Toyama in Japan, and colleagues conducted a sub-analysis of a multicenter, open-label, 52-week, randomized controlled trial oftofogliflozin as monotherapy in Japanese patients with type 2 diabetes. Patients were categorized into tertiles by baseline insulin level: low insulin (≤5.6 µU/mL), medium insulin (5.6 to 10µU/mL), and high insulin (>10µU/mL).
The researchers found that HbA1c, fasting plasma glucose levels, and body weight were significantly reduced from the baseline in all 3 groups. The changes in levels of plasma glucose AUC0-2 hours, C-peptide index AUC0-2 hours during the meal tolerance tests, and the insulin secretion index were the largest in the high group. The 3 groups were similar in terms of incidence of drug-related adverse events.
“Although tofogliflozin was effective regardless of baseline insulin level, it showed the highest efficacy in the [high] group,” conclude the authors.
Disclosures: The authors disclosed financial ties to the pharmaceutical industry. Chugai Pharmaceutical Co. funded the original phase 3 trial.
Tobe K, Suganami H, Kaku K, et al. Sodium glucose co-transporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline [published online October 15, 2017]. J Diabetes Invest. doi:10.1111/jdi.12761